OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 01, 2014
Key considerations for implementing single-use components or platforms when moving from research to process development.
Generics, market dynamics, and global demand are changing drug spending patterns.
Single-use systems and other technologies drive process efficiencies, but there is room for improvement.
With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.
Antibody fragments pose unique challenges in recovery, purification, and formulation.
Frenzy cools as investors seeking a quick return turn elsewhere.
Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.
Techniques to enable the design and formulation of stable, protein-based therapeutics.
Regulators work with manufacturers to improve systems for measuring product performance and manufacturing reliability.
Criticality is used as a risk-based tool to drive control strategies.
The R&D model is in transition and creating new demands on contract services providers.
Click the title above to open the BioPharm International January 2014 issue in an interactive PDF format.